{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:48:14Z","timestamp":1792068494068,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clineuro.2026.109624","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:20:15Z","timestamp":1787325615000},"page":"109624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rituximab treatment in AChR-positive generalized myasthenia gravis within two years of diagnosis"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4652-3582","authenticated-orcid":false,"given":"Vasiliki","family":"Zouvelou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigli G.","family":"Vakrakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Tzavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Strataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasos","family":"Tsokkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleopas A.","family":"Kleopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Belimezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clineuro.2026.109624_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy asthma clinical immunology official journal Canadian Society Allergy Clinical Immunology"},{"issue":"1","key":"10.1016\/j.clineuro.2026.109624_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"8","key":"10.1016\/j.clineuro.2026.109624_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2026.109624_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.clineuro.2026.109624_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109624_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000534336","article-title":"Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis","volume":"86","author":"Ren","year":"2023","journal-title":"Eur. Neurol."},{"issue":"8","key":"10.1016\/j.clineuro.2026.109624_bib7","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109624_bib8","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Task. Force Med. Sci. Advis. Board. Myasthenia Gravis Found. Am. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2026.109624_bib9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J. Neurol."},{"issue":"25","key":"10.1016\/j.clineuro.2026.109624_bib10","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.clineuro.2026.109624_bib11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109624_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai","year":"2020","journal-title":"Muscle & nerve"},{"issue":"5","key":"10.1016\/j.clineuro.2026.109624_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/pn-2025-004655","article-title":"Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)","volume":"25","author":"Jacob","year":"2025","journal-title":"Pract. Neurol."},{"issue":"5","key":"10.1016\/j.clineuro.2026.109624_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109624_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2026.109624_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J. Neuroimmunol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726003161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726003161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:01:56Z","timestamp":1792065716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726003161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":16,"alternative-id":["S0303846726003161"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109624","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab treatment in AChR-positive generalized myasthenia gravis within two years of diagnosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109624"}}